How Does Primolut N Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Primolut N Works
- Active ingredient: Norethisterone, a synthetic progestogen
- Primary action: Binds to progesterone receptors in the uterus and pituitary
- Endometrial effect: Stabilises the womb lining, preventing breakthrough bleeding
- Hormonal feedback: Suppresses gonadotropins (LH, FSH), delaying ovulation when taken continuously
- Onset: Peak levels reached 1–2 hours after oral dose
- Duration: Withdrawal bleed typically 2–3 days after last tablet
Primolut N contains norethisterone, a progestogen hormone that mimics the action of natural progesterone. By activating progesterone receptors in key tissues, it regulates the menstrual cycle, treats endometriosis, and can delay periods when taken under medical supervision.
Important Medical Advice
If you experience sudden chest pain, shortness of breath, severe headache, or painful swelling in one leg while taking Primolut N, seek immediate medical attention – these could be signs of a blood clot. Also stop and contact your doctor if you develop jaundice (yellow skin/eyes) or migraines for the first time.
Chemical Composition & Molecular Structure
Norethisterone (also called norethindrone) is a 19‑nortestosterone derivative – a synthetic progestogen with structural similarities to both progesterone and testosterone, but optimised for oral activity and receptor selectivity.
Structural Details
17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one
The ethinyl group at position 17 makes it orally active by slowing liver metabolism.
C20H26O2
Molecular weight: 298.42 g/mol (as base). Primolut N contains 5 mg norethisterone per tablet.
3‑keto, 17α‑ethinyl, 17β‑hydroxy
The 17α‑ethinyl group prevents rapid first‑pass inactivation, allowing oral administration.
| Property | Value | Clinical Significance |
|---|---|---|
| Bioavailability | ~64% (oral) | Good absorption; first‑pass metabolism moderate |
| Protein binding | 97% (mainly albumin) | High binding affects distribution and interactions |
| Receptor affinity | High for progesterone receptor (PR), weak for androgen receptor | Progestogenic potency ~1.3× that of natural progesterone |
🗒️ Pharmaceutical insight: The 19‑nor structure (removal of carbon‑19 methyl group) reduces androgenic side effects compared to older progestogens, while maintaining strong progestogenic activity.
Mechanism of Action: Progesterone Receptor Binding
Norethisterone exerts its effects primarily by binding to intracellular progesterone receptors (PR) in target tissues – uterus, pituitary, hypothalamus, and breast.
- Receptor activation: Norethisterone diffuses into cells and binds to PR‑A and PR‑B isoforms.
- Gene transcription: The hormone‑receptor complex modulates transcription of progesterone‑responsive genes.
- Endometrial transformation: In the uterus, it converts proliferative endometrium into secretory endometrium, stabilising the lining.
- Pituitary feedback: It suppresses gonadotropin (LH, FSH) secretion, which can inhibit ovulation when taken continuously.
- Cervical mucus: Thickens cervical mucus, hindering sperm penetration (minor contribution).
🗒️ Physiological insight: Unlike natural progesterone, norethisterone also has weak androgenic and oestrogenic properties, which contribute to both therapeutic effects and possible side effects (e.g., acne, fluid retention).
Receptor Selectivity & Tissue Effects
Norethisterone is highly selective for progesterone receptors but also interacts with other steroid receptors, explaining its unique profile.
| Receptor type | Relative affinity | Clinical consequence |
|---|---|---|
| Progesterone receptor (PR) | High (130% of natural progesterone) | Strong progestogenic action – endometrial stabilisation, period delay |
| Androgen receptor (AR) | Low (~30% of testosterone) | Possible androgenic effects: acne, oily skin at high doses |
| Oestrogen receptor (ER) | Very low | No direct oestrogenic effect, but some metabolites have weak oestrogenicity |
| Mineralocorticoid receptor | Minimal | No significant salt‑retaining activity |
This receptor profile means Primolut N effectively mimics the luteal phase of the menstrual cycle, maintaining the endometrium and preventing breakthrough bleeding.
Metabolic Effects & Half‑Life
Norethisterone is extensively metabolised in the liver, primarily by reduction and hydroxylation, then conjugated to glucuronides and sulphates. The major active metabolite is 5α‑dihydronorethisterone.
Hepatic metabolism
Enzymes: CYP3A4 (major), CYP2C9, CYP2C19
Pathways: A‑ring reduction, ethinyl group oxidation
Elimination half‑life
Parent drug: 5–12 hours
Active metabolites: similar duration
Excretion
Urine: ~40% (as metabolites)
Faeces: ~60%
The half‑life supports once‑ or twice‑daily dosing. When treatment stops, hormone levels drop quickly, triggering a withdrawal bleed within 2–3 days – the basis of period delay and cycle regulation.
🗒️ Metabolic insight: Drugs that induce CYP3A4 (e.g., rifampicin, St John’s wort) can accelerate norethisterone metabolism, reducing efficacy. Conversely, CYP3A4 inhibitors (e.g., ketoconazole) may increase levels.
Absorption, Distribution & Elimination
Absorption
Peak plasma: 1–2 hours
Food effect: minimal delay
Distribution
Volume: ~4 L/kg
Protein binding: 97% (albumin, SHBG)
Elimination
Clearance: ~6 mL/min/kg
Steady state: reached in 5 days
Norethisterone crosses the placental barrier and is distributed into breast milk. Therefore it is contraindicated in pregnancy and breastfeeding.
Clinical Efficacy for Period Disorders
Based on the PIL and clinical studies, Primolut N is effective in several gynaecological conditions:
| Indication | Dosing example | Mechanism applied |
|---|---|---|
| Irregular/heavy periods | 5 mg 2–3 times daily from day 16–25 of cycle | Stabilises endometrium, reduces menstrual loss |
| Endometriosis | Continuous 10–15 mg daily for 6–9 months | Decidualisation and atrophy of ectopic endometrial tissue |
| Premenstrual syndrome | 5 mg 2–3 times daily from day 16–25 | Hormonal stabilisation, modulates neurotransmitters |
| Delay of period | 5 mg 3 times daily starting 3 days before expected period | Maintains progesterone effect, postpones withdrawal bleed |
Efficacy rates: period delay success >90% when taken correctly; endometriosis pain reduction in ~70% of women.
Primolut N Mechanism FAQs
How does Primolut N delay a period?
It maintains high progestogen levels, keeping the endometrium stable. When you stop taking it, hormone levels drop and a withdrawal bleed occurs, usually within 2–3 days.
Does Primolut N stop ovulation?
When taken continuously at therapeutic doses (e.g., 10–15 mg daily), it suppresses LH and FSH, which can inhibit ovulation. At lower doses used for cycle regulation, ovulation may still occur.
How quickly does Primolut N start working?
Norethisterone reaches peak blood levels within 1–2 hours. For period delay, it should be started 3 days before your expected period to be effective.
Can Primolut N help with endometriosis pain?
Yes, continuous treatment for 6–9 months causes decidualisation and shrinkage of endometrial implants, reducing pain and bleeding.
Is Primolut N the same as progesterone?
No, it is a synthetic progestogen (norethisterone) that mimics progesterone but has a longer half‑life and is orally active. Natural progesterone cannot be taken orally as effectively.
Need Primolut N with Medical Guidance?
If you're considering using Primolut N for period delay, endometriosis, or irregular periods, speak with a UK-registered doctor through a confidential online consultation.
Secure Prescription & Next-Day Delivery
MHRA-compliant | GPhC-registered pharmacy | Discreet packaging | UK doctors
Start Period Delay ConsultationRelated Primolut N Guides
Medical Content Manager
Nabeel is a co-founder, and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.
Medical Doctor
Dr. Feroz is a GMC-registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.
Medical Director
Usman is a co-founder, and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.
Review Date: 20 February 2026
Next Review: 20 August 2026
Published on: 20 February 2026
Last Updated: 20 February 2026